← Back to Clinical Trials
Recruiting Phase 2 NCT06482515

NCT06482515 Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06482515
Status Recruiting
Phase Phase 2
Sponsor University of Maryland, Baltimore
Condition Neoplasms
Study Type INTERVENTIONAL
Enrollment 96 participants
Start Date 2024-11-04
Primary Completion 2028-05-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Time-restricted eatingNutrition counseling

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 96 participants in total. It began in 2024-11-04 with a primary completion date of 2028-05-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Cancer-related fatigue affects at least 30-90% of patients with cancer, depending on the type of cancer and their treatment(s) (e.g., chemotherapy, radiation). It is not relieved by sleep or rest, and it sometimes can persist for years after a person's cancer was treated. The fatigue can be so bad that people cannot return to work, hobbies, family roles, or other daily activities, thereby greatly reducing quality of life. The causes of this fatigue are unknown, and we currently do not have anything that can reliably prevent or cure the fatigue. However, there are recent data suggesting that circadian rhythm, or a person's internal body clock, may be disrupted by the cancer experience and contribute to fatigue. Food intake is an external cue that can entrain circadian rhythm. We recently showed that cancer survivors are willing and able to eat all their food within a 10-hour eating window-a practice called time-restricted eating. Herein, we are testing time-restricted eating against a control group (matched for time-, attention, and expectancy) to see if time-restricted eating can indeed alleviate cancer-related fatigue. All participants will be asked to use the myCircadianClock smartphone app to log their food intake and weekly body weight measurements. The participants assigned to the time-restricted eating group will be asked to eat all their food in a 10-hour window during the day. People can choose their start time based on their schedule and preferences, but we ask that the window is the same for the whole study (e.g., 7am-5pm,9:30am-7:30pm). Black coffee and unsweetened tea are allowed before the eating window, and water and medicines are allowed at all times. The participants in the control group will meet with a nutritionist to discuss the American Cancer Society nutrition guidelines in cancer survivorship; they will not be restricted to when they can eat. Participants in both groups will give us valuable information regarding how diet is related to the experience of fatigue. The purpose of this study is to test the effects of a 12-week TRE intervention vs. an unrestricted eating pattern on fatigue, the sustainability of the program at 24 weeks, and the effects of TRE on circadian rhythm and sugar metabolism.

Eligibility Criteria

Inclusion criteria (Participants must…): * Have a diagnosis of a hematologic neoplasm (e.g., leukemia, lymphoma, multiple myeloma); * Be at least 2 months post-treatment with chemotherapy, radiation, targeted therapy, chimeric antigen receptor (CAR)-T cell therapy, stem cell transplant, or another therapy (maintenance therapies are okay; steady unchanged treatment for relapsed disease for \>2 months and expected to stay on it until progression is okay); * Have a baseline level of fatigue, as determined by at least one of the following: 1. Reporting a score of 4 or higher in response to the question, "What was your worst fatigue in the last week, on a scale of 0-10, where 0 is no fatigue and 10 is the worst fatigue?" 2. In the habit of taking daytime naps, 3. Have fatigue that interferes with their ability to work, engage in social events, or is more than would be expected from physical exertion, * Be able to speak and/or read and write in English or Spanish; * Be at least 18 years old; and * Be able to provide informed consent. Exclusion criteria (participants must not…) * Be underweight, as defined as a body mass index \<18.5 kg/m2; * Already eat all their food within a window that is 10 h or shorter most (6/7) days of the week; * Be employed in a job where they regularly work away from the home at night (e.g., night shift); * Have surgery planned during the study duration; * Have any contraindications to the proposed nutrition intervention as identified by their medical provider, their designee, or the study team (e.g., type 1 diabetes, risk for hypoglycemia, medication requirements, pregnancy, breastfeeding, recent history of an eating disorder); * Be taking insulin; or * Be on enteral or parenteral nutrition.

Contact & Investigator

Central Contact

Amber Kleckner

✉ amber.kleckner@umaryland.edu

📞 4107065961

Frequently Asked Questions

Who can join the NCT06482515 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06482515 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT06482515 currently recruiting?

Yes, NCT06482515 is actively recruiting participants. Contact the research team at amber.kleckner@umaryland.edu for enrollment information.

Where is the NCT06482515 trial being conducted?

This trial is being conducted at Baltimore, United States.

Who is sponsoring the NCT06482515 clinical trial?

NCT06482515 is sponsored by University of Maryland, Baltimore. The trial plans to enroll 96 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology